Hexagon Nutrition Limited and Particles for Humanity have successfully completed the commercial-scale process validation of PFH-VAP, a stable formulation of Vitamin A Palmitate designed for large-scale food fortification.

The product is proposed to be commercially marketed under the brand name VIT A+ in international markets. This milestone demonstrates the feasibility of the manufacturing process at a commercial scale, supporting the objective of enabling effective and stable delivery of Vitamin A through fortified food products.

Product Details and Milestone

The development involves a collaboration between Hexagon Nutrition and Particles for Humanity. The successful validation marks a significant step in scaling up the production capabilities for this specific nutritional intervention.

Next Steps

The company stated that it will continue to undertake necessary steps towards the commercialisation of VIT A+. These actions are subject to applicable regulatory and commercial requirements. The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Hexagon Nutrition Limited has scheduled a Board of Directors meeting for September 30, 2026, to consider significant corporate governance matters. The agenda includes reviewing requisitions for the appointment of a new Executive Director and Chairman, as well as the approval of remuneration for the current Managing Director.

Requisition for Executive Director and Chairman

The Board will take note of a requisition letter dated September 24, 2026, submitted under Section 100(2) of the Companies Act, 2013. This request comes from Dr. Nikhil Arun Kelkar and Mr. Vikram Arun Kelkar, who are Promoters and Shareholders holding a combined 38.41% of the company's shareholding.

The requisition seeks the appointment of Mr. Arun Purushottam Kelkar (DIN: 00171276) as the Executive Director and Chairman. This proposal follows a notice of candidature received under Section 160(1) of the Companies Act, 2013. Additionally, the Board is asked to approve the remuneration payable to Mr. Arun Purushottam Kelkar for his term and to convene an Extra-ordinary General Meeting (EGM) to ratify these decisions.

Remuneration Approval for Managing Director

A separate requisition, also dated September 24, 2026, was submitted by Dr. Nikhil Arun Kelkar and Ms. Anuradha Kelkar. These shareholders and promoter members hold a combined 24.67% of the shareholding. They have requested the approval of remuneration payable to Mr. Vikram Kelkar, the current Managing Director (DIN: 02302364), effective from April 1, 2026.

Similar to the first requisition, this group has called for an EGM to be convened to address these matters. The Board is scheduled to take note of this request during the September 30 meeting.

Meeting Details and Regulatory Compliance

The meeting is being held in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both the National Stock Exchange of India Limited and BSE Limited about the scheduled board meeting.

The company stated that further details regarding the meeting will be made available on its official website. The Board will also consider and transact such other business as may be decided by the Chairperson with the consent of the Board.